Viking Therapeutics Inc. (NASDAQ:VKTX) shares are trading lower by at least 15% on Thursday as investors digest news of an upsized equity offering and convertible senior notes financing, while S&P 500 futures are down 0.5%.
• Viking Therapeutics stock is showing notable weakness. What’s pressuring VKTX stock?
Viking Therapeutics (VKTX) Stock Drops After Upsized Financing
The clinical-stage biopharmaceutical company priced its concurrent public offerings of 7.85 million shares at $35 per share, and $225 million in 2% convertible senior notes due 2032.
Viking estimates that the net proceeds from the common stock offering will be approximately $258.2 million (or approximately $297 million if the underwriters fully exercise their option to purchase additional shares).
The company will use the capital for the continued clinical development, advancement, and commercialization of its VK2735 program, VK3019 program, and for other general research and development, working capital, and general corporate purposes.
VKTX Technical Analysis: Key Support, Resistance and Trend
With the stock at $36, the price is still holding above its major trend gauges — about 8.3% above the 20-day SMA ($33.16) and roughly 7.8% above the 200-day SMA ($33.31) — which suggests the longer-term uptrend hasn’t fully broken despite today’s sharp pullback.
The nearby $36.50 area is the first spot where rebounds can stall, while $31.50 is the key downside level to watch if selling continues.
RSI is the cleaner momentum read right now: at 54.83, it’s neutral, implying the move isn’t “stretched” enough to be automatically overbought or oversold.
The moving-average structure is mixed: the 20-day SMA is below the 50-day SMA (a short-term bearish crossover), but the 50-day SMA remains above the 200-day SMA, keeping the July golden cross backdrop intact.
Historically, the stock saw RSI overbought conditions in September and oversold conditions in February, so traders will be watching whether this drop pushes momentum back toward the lower end of its recent range.
- Key Resistance: $36.50 — Nearby pivot area where rebounds can stall after a sharp down session.
- Key Support: $31.50 — Prior demand zone that becomes the “line in the sand” if the pullback deepens.
See More:
Top Momentum Stocks
How Viking Therapeutics (VKTX) Ranks on Momentum
Below is the Benzinga Edge scorecard for Viking Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 89.65) — The stock has been showing strong relative strength on a multi-week basis, even with today’s drawdown.
The Verdict: Viking Therapeutics’ Benzinga Edge signal reveals a momentum-driven story, where trend-followers may stay interested as long as the stock holds above its key moving averages.
After a financing-driven sell-off, the next tradeable question is whether buyers defend support near $31.50 or whether the pullback starts to unwind the post-golden-cross trend.
VKTX Stock Price Activity: Viking Therapeutics shares were down 15.61% to $35.15 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Shutterstock
